Inflammatory breast cancer (IBC) is a rare disease that represents about two to three percent of all breast cancers and is challenging to diagnose. To improve diagnosis, researchers are working to validate a new proposed scoring system. Review the current research with Dr. Flipia Lynce, Director of the Inflammatory Breast Cancer Program at the Dana Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School.